# Catalyst Pharmaceuticals Inc. (CPRX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $3.99B  
**Price:** $31.34

> Catalyst Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, particularly in neuromuscular, neurological, and metabolic areas. Its primary products include FIRDAPSE (amifampridine phosphate), approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS); AGAMREE (vamorolone), a corticosteroid for Duchenne muscular dystrophy; and FYCOMPA (perampanel), used for focal onset seizures and tonic-clonic seizures. The company emphasizes patient accessibility through comprehensive support services, patient advocacy, and community-building initiatives to ensure seamless treatment access. Catalyst Pharmaceuticals Inc. maintains a strong U.S. commercial presence while pursuing strategic partnerships for global expansion. Guided by core values of passion, trust, and integrity, it prioritizes ethical standards and innovative therapies addressing unmet needs in small patient populations. Founded and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals Inc. plays a vital role in the rare disease sector by delivering targeted treatments that improve patient outcomes.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $589M | $502M | $258M | $214M | — |
| 2024 | $492M | $423M | $195M | $164M | — |
| 2023 | $398M | $346M | $87M | $71M | — |
| 2022 | $214M | $180M | $102M | $83M | — |
| 2021 | $141M | $119M | $52M | $39M | — |
| 2020 | $119M | $102M | $41M | $75M | — |
| 2019 | $102M | $88M | $32M | $32M | — |
| 2018 | $500,000 | — | -$35M | -$34M | — |
| 2017 | — | — | -$19M | -$18M | — |
| 2016 | — | — | -$19M | -$18M | — |
| 2015 | — | — | -$20M | -$20M | — |
| 2014 | — | — | -$15M | -$16M | — |
| 2013 | — | — | -$10M | -$12M | — |
| 2012 | — | — | -$5M | -$4M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.10B | $150M | $954M | $709M | — |
| 2024 | $851M | $124M | $728M | $518M | — |
| 2023 | $470M | $82M | $388M | $138M | — |
| 2022 | $376M | $75M | $300M | $298M | — |
| 2021 | $238M | $31M | $207M | $171M | — |
| 2020 | $192M | $23M | $170M | $130M | — |
| 2019 | $112M | $25M | $88M | $90M | — |
| 2018 | $60M | $10M | $51M | $17M | — |
| 2017 | $85M | $4M | $81M | $57M | — |
| 2016 | $42M | $2M | $39M | $14M | — |
| 2015 | $60M | $5M | $55M | $28M | — |
| 2014 | $44M | $9M | $35M | $9M | — |
| 2013 | $25M | $4M | $21M | $2M | — |
| 2012 | $17M | $2M | $15M | $1M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $209M | $58,000 | $209M |
| 2024 | $240M | $556,000 | $239M |
| 2023 | $144M | $231,000 | $143M |
| 2022 | $116M | $29,000 | $116M |
| 2021 | $60M | $1M | $59M |
| 2020 | $45M | $11,000 | $45M |
| 2019 | $35M | $19,000 | $35M |
| 2018 | -$26M | $92,018 | -$26M |
| 2017 | -$14M | — | — |
| 2013 | -$10M | $9,432 | -$10M |
| 2012 | -$5M | $52,382 | -$5M |
| 2011 | -$5M | $3,620 | -$5M |
| 2010 | -$4M | $2,867 | -$4M |
| 2009 | -$8M | $2,298 | -$8M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CPRX)